![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The authors report the results of 58 children with ALL in 2CR after related (n = 31) or unrelated (n = 27) AHSCT. Characteristics at diagnosis and initial and after relapse antileukemic treatment were similar in the related donor (RD) and the unrelated donor (UD) groups. Conditioning consisted of TBI/CY ± VP-16 for patients ≥3 years old (n = 43) and Bu/CY for the rest. Median recipient age was 8 years (range 1–17) in the RD and 9 years (range 3–14) in the UD group. Median follow-up was 54 months (range 24–80) and 52 months (range 22–85) in the RD and the UD groups repectively.The 5-year EFS probability was 43 ± 9% for the RD group and 36 ± 9% in the UD group (p =. 25). The transplant-related mortality was 16% in the RD and 37% in the UD group (p =. 016). In the RD group 36.7% of patients relapsed versus 18.6% in the UD group (p =. 05). GvHD associated with organ failure or infection caused most of the transplant-related deaths in both groups. Survivor quality of life for both groups was good (Lansky score ≤ 90).